> ## Content Index
> Fetch the complete content index at: https://members.americanhealthintel.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Doximity stock jumps 81% on AI Search guidance raise
- URL: https://members.americanhealthintel.com/2026-08-07-ledger/
- Published: 2026-08-07T16:04:18.000Z
- Updated: 2026-08-07T16:04:18.000Z
- Description: Plus: GoodRx beats and raises on Pharma Direct growth. The day's rules, money, and enforcement, sourced and tiered below.
- Author: American Health Intel

Plus: GoodRx beats and raises on Pharma Direct growth. The day's rules, money, and enforcement, sourced and tiered below.

| American Health Intel Rules · Money · Medicine · Decoded daily The Ledger Friday, August 7, 2026 Doximity stock jumps 81% on AI Search guidance raise Plus: GoodRx beats and raises on Pharma Direct growth. The day's rules, money, and enforcement, sourced and tiered below. ![](https://americanhealthintel.com/email/pulse-divider.png) Earnings Confidence: High Doximity, the professional network used by most U.S. physicians, saw its stock jump as much as 81 percent on a fiscal Q1 beat and a guidance raise built on an unbooked pharma AI ad product. Revenue hit 156.6 million dollars and full-year guidance rose to 671 to 681 million dollars. The company recognized zero dollars from AI Search this quarter, meaning investors are pricing an entirely unbooked revenue line. Why it matters A digital health company's stock jumped sharply on earnings, but the guidance raise leans on a new AI advertising product that has not yet booked revenue, so watch whether it delivers. Sources: [SEC](https://www.sec.gov/Archives/edgar/data/0001516513/000151651326000038/docs-20260806.htm?ref=members.americanhealthintel.com) · [Businesswire](https://www.businesswire.com/news/home/20260806730067/en/Doximity-Announces-Fiscal-2027-First-Quarter-Financial-Results?ref=members.americanhealthintel.com) Earnings Confidence: High GoodRx, the prescription discount and price-comparison app, beat second-quarter estimates and raised full-year guidance even as its original discount-card business kept shrinking. Legacy prescription-transaction revenue fell 26 percent to 106.4 million dollars. Pharma Direct, GoodRx's manufacturer-funded discount channel, grew 76 percent to 61.6 million dollars and now drives the growth story. Why it matters A consumer drug discount app's original business is shrinking while a pharma funded channel takes over as its growth engine. Sources: [Goodrx](https://investors.goodrx.com/news-releases/news-release-details/goodrx-reports-second-quarter-2026-results?ref=members.americanhealthintel.com) Also today iRhythm buys VitalConnect for $287.5M [Read](https://americanhealthintel.com/editions/2026-08-07-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#irhythm-vitalconnect-cardiac-monitoring-acquisition) FRONTIER SCAN: California widens corporate-practice-of-medicine crackdown [Read](https://americanhealthintel.com/editions/2026-08-07-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#ca-cpom-enforcement-wave-frontier-scan) Lane Regional Medical Center cuts 18 jobs, closes specialty clinic [Read](https://americanhealthintel.com/editions/2026-08-07-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#lane-regional-louisiana-layoffs-service-line-exit) UMass Memorial Health co-leads Wellinks' $10M Series B [Read](https://americanhealthintel.com/editions/2026-08-07-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#wellinks-umass-memorial-series-b-rpm-funding) 435Records$31.7BEnforcement19Deadlines126Rules [Read this issue + the trackers](https://americanhealthintel.com/editions/2026-08-07-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) Pick your field on the site and every story tells you what it means for you. Reply to this email and tell us what you want covered. We read everything. We show our work. We score our own calls. [Track record](https://americanhealthintel.com/ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Calendar](https://americanhealthintel.com/calendar/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Enforcement](https://americanhealthintel.com/enforcement/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [X](https://x.com/amhealthintel?ref=members.americanhealthintel.com) · [LinkedIn](https://www.linkedin.com/company/american-health-intel?ref=members.americanhealthintel.com) News and analysis, not legal, medical, coding, or investment advice.You subscribed at americanhealthintel.com · [Unsubscribe](%%{unsubscribe%5Furl}%%) |
| --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |